Addario Lung Cancer Medical Institute - ALCMI

12/28/2025

UK researchers have shown that a single circulating lung cancer cell can be detected in a routine blood sample using Fourier Transform Infrared (FT-IR) microspectroscopy.
https://buff.ly/5m19J25

See How Much You Could Save, No Minimum Order Amount. We Accept Orders From GPs, The NHS, Private Companies And Members Of The Public.

12/27/2025

2025 marked a clear inflection point in NSCLC outcomes, with multiple landmark trials and FDA approvals collectively driving the fastest decline in lung cancer mortality and pushing 5-year survival toward 30%, as highlighted in the 2025 year-in-review on NSCLC care in Physician's Weekly.

This slideshow distills the year’s most practice-changing lung cancer developments into a single, accessible overview.

12/26/2025

Osimertinib‑based combinations and next‑generation antibody–drug conjugates have created a true “problem of plenty” in EGFR‑mutated NSCLC, shifting the core challenge from drug discovery to treatment sequencing strategy.

With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.

12/25/2025

As we wrap up another year at the Addario Lung Cancer Medical Institute (ALCMI), we are filled with gratitude for the incredible community that stands with us in the fight to make lung cancer a survivable disease.

12/24/2025

A groundbreaking study from The National Institutes of Health (NIH), published in Nature, has uncovered a new cause for aggressive lung adenocarcinoma.

NIH researchers identify LINE-1–driven ID2 signature as a marker of fast-evolving, aggressive lung adenocarcinoma, offering new diagnostic and therapeutic opportunities.

12/23/2025

Non–small cell lung cancer survivors treated at Memorial Sloan Kettering Cancer Center face a clinically meaningful risk of non-lung secondary cancers, and that risk is driven far more by genetic predisposition than by smoking history, according to new data in JAMA Network Open.

12/22/2025

Congrats to GSK! The company's B7-H3–targeted antibody-drug conjugate risvutatug rezetecan (GSK’227) has been granted FDA Orphan Drug Designation for small-cell lung cancer, supported by early ARTEMIS-001 phase I data presented at WCLC 2024 and detailed in a new GSK press release.

12/21/2025

A new 15-year National Cancer Database analysis in JCO Oncology Practice reveals a significant disparity in the adoption of single-fraction stereotactic body radiation therapy (SF-SBRT) for stage I non–small cell lung cancer (NSCLC).

PURPOSETo evaluate utilization trends and survival outcomes of single-fraction stereotactic body radiation therapy (SF-SBRT) for early-stage non–small cell lung cancer (NSCLC).METHODSThe National Cancer Database (2006-2021) was queried to identify ...

12/20/2025

NYU Langone Health researchers have shown that blocking ferroptosis suppressor protein 1 (FSP1) can shrink lung adenocarcinoma tumors by up to 80% in mouse models, defining a clear metabolic vulnerability in one of the most aggressive lung cancer subtypes.

NYU Langone researchers found that blocking a single protein in the body can trigger a form of self-destruction in lung cancer cells, according to a November study that identified a potential strategy for treating lung adenocarcinoma, one of the most aggressive forms of cancer types. Using genetical...

12/19/2025

Exciting research! Mobile DNA reactivation has been identified as a previously unrecognized engine of aggressive lung adenocarcinoma by a National Institutes of Health-led international team using whole-genome data from the Sherlock-Lung study.

New research has identified key factors that drive lung tumor evolution and influence outcomes, describing a previously unknown origin of some aggressive lung cancers.

12/18/2025

ERBB2 signaling emerges as a central driver of immune evasion and immunotherapy resistance in small cell lung cancer, as demonstrated by Lydia Meder, Charlotte Isabelle Orschel, and colleagues in Nature Communications.

While the emergence of immune checkpoint inhibitors has improved outcomes in patients with small cell lung cancer (SCLC), tumour that develop means of immune evasion become resistant. Here, the authors report that ERBB2 signalling induces loss of MHC Class I expression and subsequently immune evasio...

12/17/2025

EGFR‑mutated lung cancer has become a true sequencing challenge, not a single‑TKI story, as outlined by Girindra Raval, MD, of the Georgia Cancer Center in a recent Cancer Network interview.

An oncologist at the Georgia Cancer Center discussed the evolution of treatment strategies and emerging therapies for patients with EGFR-mutated disease.